<ul>
	<li>Docetaxel should be administered under the supervision of a physician experienced in the use of antineoplastic agents</li>
	<li>There is a higher risk of developing severe adverse reactions including toxic death and fatal gastrointestinal hemorrhage in patients with hepatic impairment</li>
	<li>Docetaxel therapy should not be given to patients with neutrophil counts of less than 1,500 cells/mm3</li>
	<li>Fatal cases of enterocolitis, including ischemic colitis, colitis and neutropenic enterocolitis have been reported&nbsp;</li>
	<li>Severe hypersensitivity reactions, with a potential fatal outcome, requiringb immediate discontinuation of Docetaxel may occur. Patients should be closely monitored&nbsp;</li>
	<li>Treatment related acute myeloid leukemia may occur. No studies have been conducted to assess the carcinogenic potential of Docetaxel</li>
</ul>